Min Hye Kyu, Lee Sooji, Kim Soeun, Son Yejun, Park Jaeyu, Kim Hyeon Jin, Lee Jinseok, Lee Hayeon, Smith Lee, Rahmati Masoud, Kang Jiseung, Papadopoulos Nikolaos G, Cho Seong H, Hahn Jong Woo, Yon Dong Keon
Department of Otorhinolaryngology-Head and Neck Surgery, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.
Department of Medicine, Graduate School, Kyung Hee University, Seoul, Korea.
Clin Exp Allergy. 2025 Jan;55(1):52-66. doi: 10.1111/cea.14592. Epub 2024 Nov 7.
Data on the global prevalence of chronic rhinosinusitis (CRS) is significantly varied and limited across countries and over time. Therefore, we aimed to conduct a comprehensive investigation into the global, regional, and national burden of CRS from the years 1980 to 2021, as well as identify those factors that influence levels of such burden.
We conducted a systematic review and meta-analysis of general population-based observational studies focusing on CRS. We calculated pooled estimates of CRS prevalence and incidence with 95% confidence intervals (CIs). Subgroup analyses were conducted stratifying by sex, age cohorts, geographic regions, smoking status, obesity, and comorbid conditions.
PubMed/MEDLINE, EMBASE, CINAHL, Google Scholar, and Cochrane databases.
We included general population-based observational studies on CRS published from database inception through October 20, 2023.
A total of 28 eligible studies, encompassing more than 237 million participants and 11,342,923 patients with CRS from 20 countries across four continents, were included in the analysis. Global pooled prevalence of CRS and CRS with nasal polyps (CRSwNP) was found to be 8.71% (95% CI, 6.69-11.33; number of studies, 20) and 0.65% (95% CI, 0.56-0.75; number of studies, 4), respectively. The prevalence of CRS was greater in Europe compared with North America, South America, and Asia; adults compared with children; smokers compared with never-smoker; those with obesity compared with normal weight; and those with comorbidities such as asthma, diabetes mellitus, eczema, and nasal septal deviation. Pooled prevalence of CRS increased from 1980 to 2020 (1980-2000: 4.72%; 95% CI, 2.12-10.49; 2014-2020: 19.40%; 95% CI, 12.12-31.07). Similar patterns were observed in CRS incidence.
Our study provides valuable insights into CRS prevalence and incidence across diverse demographic and clinical factors, highlighting its increasing global burden. The reported prevalence of CRS varies internationally, and may be increasing over time. To enhance data quality and comparability, standardization of reporting methodologies is imperative.
PROSPERO (registration no. CRD42024527805).
关于慢性鼻-鼻窦炎（CRS）全球患病率的数据在不同国家和不同时期差异显著且有限。因此，我们旨在全面调查1980年至2021年全球、区域和国家层面CRS的负担情况，并确定影响该负担水平的因素。
我们对基于普通人群的CRS观察性研究进行了系统评价和荟萃分析。我们计算了CRS患病率和发病率的合并估计值以及95%置信区间（CI）。按性别、年龄组、地理区域、吸烟状况、肥胖和合并症进行亚组分析。
PubMed/MEDLINE、EMBASE、CINAHL、谷歌学术和Cochrane数据库。
我们纳入了从数据库建立至2023年10月20日发表的基于普通人群的CRS观察性研究。
分析共纳入了28项符合条件的研究，涉及来自四大洲20个国家的超过2.37亿参与者和11342923例CRS患者。CRS和伴鼻息肉的CRS（CRSwNP）的全球合并患病率分别为8.71%（95%CI，6.69-11.33；研究数量，20）和0.65%（95%CI，0.56-0.75；研究数量，4）。与北美洲、南美洲和亚洲相比，欧洲CRS的患病率更高；成年人高于儿童；吸烟者高于从不吸烟者；肥胖者高于正常体重者；以及患有哮喘、糖尿病、湿疹和鼻中隔偏曲等合并症者。CRS的合并患病率从1980年至2020年有所增加（1980-2000年：4.72%；95%CI，2.12-10.49；2014-2020年：19.40%；95%CI，12.12-31.07）。CRS发病率也观察到类似模式。
我们的研究为不同人口统计学和临床因素下CRS的患病率和发病率提供了有价值的见解，凸显了其不断增加的全球负担。报告的CRS患病率在国际上存在差异，且可能随时间增加。为提高数据质量和可比性，报告方法的标准化势在必行。
PROSPERO（注册号CRD42024527805）
